生物标志物
肿瘤科
医学
背景(考古学)
队列
内科学
逻辑回归
载脂蛋白E
疾病
认知障碍
阿尔茨海默病
免疫学
生物
生物化学
古生物学
作者
Angharad R. Morgan,Samuel Touchard,Claire Alexandra Leckey,Caroline O’Hagan,Alejo J. Nevado‐Holgado,Frederik Barkhof,Lars Bertram,Olivier Blin,Isabelle Bos,Valerija Dobričić,Sebastiaan Engelborghs,Giovanni Battista Frisoni,Lutz Frölich,Silvey Gabel,Peter Johannsen,Petronella Kettunen,Iwona Kłoszewska,Cristina Legido‐Quigley,Alberto Lleó,Pablo Martínez‐Lage
标识
DOI:10.1016/j.jalz.2019.03.007
摘要
INTRODUCTION: Plasma biomarkers for Alzheimer's disease (AD) diagnosis/stratification are a "Holy Grail" of AD research and intensively sought; however, there are no well-established plasma markers. METHODS: A hypothesis-led plasma biomarker search was conducted in the context of international multicenter studies. The discovery phase measured 53 inflammatory proteins in elderly control (CTL; 259), mild cognitive impairment (MCI; 199), and AD (262) subjects from AddNeuroMed. RESULTS: Ten analytes showed significant intergroup differences. Logistic regression identified five (FB, FH, sCR1, MCP-1, eotaxin-1) that, age/APOε4 adjusted, optimally differentiated AD and CTL (AUC: 0.79), and three (sCR1, MCP-1, eotaxin-1) that optimally differentiated AD and MCI (AUC: 0.74). These models replicated in an independent cohort (EMIF; AUC 0.81 and 0.67). Two analytes (FB, FH) plus age predicted MCI progression to AD (AUC: 0.71). DISCUSSION: Plasma markers of inflammation and complement dysregulation support diagnosis and outcome prediction in AD and MCI. Further replication is needed before clinical translation.
科研通智能强力驱动
Strongly Powered by AbleSci AI